{"title":"急性淋巴细胞白血病患者罕见的嗜碳细胞吞噬菌血症。","authors":"Haruki Naruse, Tomoya Maeda, Noriyuki Watanabe, Mieko Tokano, Sachie Koyama, Sachi Tanaka, Yoshitada Taji, Norihito Tarumoto, Naoki Takahashi, Kotaro Mitsutake, Yasuhiro Ebihara","doi":"10.1016/j.jiac.2025.102771","DOIUrl":null,"url":null,"abstract":"<p><p>Capnocytophaga sputigena, a species of bacteria resident in the human oral cavity, can rarely cause opportunistic infections in immunocompromised patients. The present case concerns a 40-year-old man with acute lymphoblastic leukemia, diagnosed in 2001, who underwent two hematopoietic stem cell transplants and had experienced relapses and remissions over nearly a 20-year period. Because his acute lymphoblastic leukemia was refractory, he was no longer receiving active treatment and was instead managed with supportive care. Under these circumstances, he developed febrile neutropenia with stomatitis, and C. sputigena was detected in blood culture. Cefepime was ineffective, but the patient's symptoms improved with tazobactam/piperacillin. The isolate was found to harbor the resistance genes Capnocytophaga sputigena β-lactamase-1 (CSP-1), cfxA3, and erm(F). The simultaneous presence of both CSP-1 and cfxA3 genes is rare. Since standard drug susceptibility testing forC. sputigenahas not yet been established, it is important to establish a standard drug susceptibility test for the appropriate treatment of C. sputigena. And physicians should consider the possibility that C. sputigena may be the causative microorganism in febrile neutropenia associated with oral mucosal injury.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102771"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rare Capnocytophaga sputigena bacteremia in a patient with acute lymphoblastic leukemia.\",\"authors\":\"Haruki Naruse, Tomoya Maeda, Noriyuki Watanabe, Mieko Tokano, Sachie Koyama, Sachi Tanaka, Yoshitada Taji, Norihito Tarumoto, Naoki Takahashi, Kotaro Mitsutake, Yasuhiro Ebihara\",\"doi\":\"10.1016/j.jiac.2025.102771\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Capnocytophaga sputigena, a species of bacteria resident in the human oral cavity, can rarely cause opportunistic infections in immunocompromised patients. The present case concerns a 40-year-old man with acute lymphoblastic leukemia, diagnosed in 2001, who underwent two hematopoietic stem cell transplants and had experienced relapses and remissions over nearly a 20-year period. Because his acute lymphoblastic leukemia was refractory, he was no longer receiving active treatment and was instead managed with supportive care. Under these circumstances, he developed febrile neutropenia with stomatitis, and C. sputigena was detected in blood culture. Cefepime was ineffective, but the patient's symptoms improved with tazobactam/piperacillin. The isolate was found to harbor the resistance genes Capnocytophaga sputigena β-lactamase-1 (CSP-1), cfxA3, and erm(F). The simultaneous presence of both CSP-1 and cfxA3 genes is rare. Since standard drug susceptibility testing forC. sputigenahas not yet been established, it is important to establish a standard drug susceptibility test for the appropriate treatment of C. sputigena. And physicians should consider the possibility that C. sputigena may be the causative microorganism in febrile neutropenia associated with oral mucosal injury.</p>\",\"PeriodicalId\":16103,\"journal\":{\"name\":\"Journal of Infection and Chemotherapy\",\"volume\":\" \",\"pages\":\"102771\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Infection and Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jiac.2025.102771\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jiac.2025.102771","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Rare Capnocytophaga sputigena bacteremia in a patient with acute lymphoblastic leukemia.
Capnocytophaga sputigena, a species of bacteria resident in the human oral cavity, can rarely cause opportunistic infections in immunocompromised patients. The present case concerns a 40-year-old man with acute lymphoblastic leukemia, diagnosed in 2001, who underwent two hematopoietic stem cell transplants and had experienced relapses and remissions over nearly a 20-year period. Because his acute lymphoblastic leukemia was refractory, he was no longer receiving active treatment and was instead managed with supportive care. Under these circumstances, he developed febrile neutropenia with stomatitis, and C. sputigena was detected in blood culture. Cefepime was ineffective, but the patient's symptoms improved with tazobactam/piperacillin. The isolate was found to harbor the resistance genes Capnocytophaga sputigena β-lactamase-1 (CSP-1), cfxA3, and erm(F). The simultaneous presence of both CSP-1 and cfxA3 genes is rare. Since standard drug susceptibility testing forC. sputigenahas not yet been established, it is important to establish a standard drug susceptibility test for the appropriate treatment of C. sputigena. And physicians should consider the possibility that C. sputigena may be the causative microorganism in febrile neutropenia associated with oral mucosal injury.
期刊介绍:
The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.